Financiere de Tubize (LTS:0D53) ROCE % : 10.26% (As of Jun. 2024)

View and export this data going back to 2007. Start your Free Trial

What is Financiere de Tubize ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Financiere de Tubize's annualized ROCE % for the quarter that ended in Jun. 2024 was 10.26%.

Financiere de Tubize ROCE % Historical Data

The historical data trend for Financiere de Tubize's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Financiere de Tubize ROCE % Chart

Financiere de Tubize Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

Get a 7-Day Free Trial

11.11

9.51

3.78

5.03

5.15

Financiere de Tubize Semi-Annual Data
	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24
ROCE %	Get a 7-Day Free Trial															6.75	-0.04	10.25	-0.08	10.26

Financiere de Tubize ROCE % Calculation

Financiere de Tubize's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	91.446	/	( ( (1838.806 - 86.732)	+	(1920.244 - 122.715) )	/ 2 )
	=	91.446	/	( (1752.074	+	1797.529)	/ 2 )
	=	91.446	/	1774.8015
	=	5.15 %

Financiere de Tubize's ROCE % of for the quarter that ended in Jun. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Jun. 2024 )		(Q: Dec. 2023 )		(Q: Jun. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Jun. 2024 )		(Q: Dec. 2023 )		(Q: Jun. 2024 )
	=	189.158	/	( ( (1920.244 - 122.715)	+	(1921.217 - 31.685) )	/ 2 )
	=	189.158	/	( ( 1797.529	+	1889.532 )	/ 2 )
	=	189.158	/	1843.5305
	=	10.26 %

(1) Note: The EBIT data used here is two times the semi-annual (Jun. 2024) EBIT data.

Financiere de Tubize (LTS:0D53) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Financiere de Tubize ROCE % Related Terms

Thank you for viewing the detailed overview of Financiere de Tubize's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Financiere de Tubize Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Financiere de Tubize SA (LTS:0D53) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

FTD:Germany TUB:Belgium

Address

Allee de la Recherche, 60, Brussels, BEL, 1070

Website

https://www.financiere-tubize.be

Financiere de Tubize SA is a holding company that owns a stake in UCB, a biopharmaceutical company. UCB is a global biotechnology company that develops treatments for conditions related to neurology and immunology. UCB generates the vast majority of its revenue in the United States, followed by Europe and other international markets. Most of its sales revenue is derived from its neurology products, followed by its immunology products. The company's strategy focuses on leveraging scientific advances and skills in areas such as genetics, biomarkers, and human biology.

Financiere de Tubize Headlines

No Headlines